When biotech investors talk about the future of DNA sequencing, they inevitably focus on industry leader Illumina (NASDAQ: ILMN). But when biotech researchers talk about the future of DNA sequencing, the conversation almost always centers on privately held Oxford Nanopore Technologies, which is developing a new approach to reading genetic code called nanopore sequencing.